Croda reported faster profit growth than sales in the first half of 2026, supported by strong Consumer Care demand, a richer product mix and benefits from its internal transformation program.
For the six months ended June 30, sales increased 2.9% to £880.5 million, or 4.6% on an organic basis. Adjusted operating profit rose 6.1% to £155.8 million, representing 6.7% organic growth, while the adjusted operating margin expanded from 17.2% to 17.7%.
On a statutory basis, operating profit increased 22.4% to £115.5 million and profit before tax rose 25.6% to £107.4 million. Free cash flow increased 36.8% to £38.3 million.
The gap between sales and profit growth indicates that Croda’s improvement came not only from higher demand, but also from pricing, product mix and greater operating efficiency.
Beauty Actives led the portfolio
Organic sales in Consumer Care increased 8%, making it the strongest of Croda’s principal divisions.
Within the segment:
Beauty Actives grew 19%
Home Care increased 9%
Fragrances & Flavours rose 8%
Beauty Care advanced 4%.
Beauty actives are generally used at relatively low inclusion rates in skin care, anti-aging, moisturization and scalp-care formulations, but they can command higher value because of their performance claims, scientific evidence and formulation support.
Croda said organic sales of New and Protected Products increased 6.9%, faster than group sales, suggesting customers continued to prioritize differentiated and innovation-led ingredients.
The company also reported 44% growth in ceramide sales after a slow period following the acquisition of that business. Ceramides are widely used in skin-barrier and premium skin-care formulations, making the increase consistent with broader demand for efficacy-based beauty ingredients.
Affordable beauty is becoming an important growth category
Croda said it was gaining share in “affordable beauty,” while premium product categories at its customers were also performing well.
The comment suggests that beauty demand is not dividing neatly between luxury growth and mass-market weakness. Consumers may reduce discretionary spending but still purchase products offering visible or scientifically supported benefits at accessible prices.
For ingredient companies, this creates demand for formulations that combine performance, stability and cost control. Beauty Actives’ 19% growth indicates that ingredients with a clear function and supporting technical data can continue to command stronger demand than more commoditized materials.
Life Sciences remained mixed
Organic sales in Life Sciences were flat. Pharma increased 1% and Seed grew 4%, while Crop Protection declined 2%.
Performance also varied within Pharma. Ingredients, representing more than 70% of pharmaceutical sales, grew 7%, while Solutions declined 17% because of project timing. Croda expects project revenue to improve during the second half.
The figures do not yet represent a broad pharmaceutical recovery. Established high-performance ingredients improved, but project-based solutions remained sensitive to customer development schedules and revenue recognition.
Crop Protection continued to face weaker conditions. Croda had already noted that the business was no longer benefiting from the customer inventory rebuilding that supported results in 2025.
Transformation benefits are reaching the margin
Management attributed the profit increase to both innovation-led growth and the company’s transformation plan. Adjusted operating margin rose by 0.5 percentage points, with further efficiency benefits expected during the second half.
Croda also completed an expansion in Asia, opening two new production facilities in India and China. Local manufacturing can reduce lead times and allow closer cooperation with regional beauty, fragrance and pharmaceutical customers.
The next test will be whether these efficiency gains remain sustainable if raw-material, energy or labor costs increase, and whether Beauty Actives growth broadens across the portfolio rather than remaining concentrated in selected products.
Full-year guidance remains unchanged
Croda maintained its full-year outlook despite geopolitical and macroeconomic uncertainty. It continues to expect 3%–6% organic sales growth and a further increase in adjusted operating margin. The company said the Middle East situation had only a limited impact on second-quarter sales.
The results point to a clear divergence across end markets:
Beauty, Home Care and Fragrances & Flavours are growing strongly, Pharma is being rebalanced, and Crop Protection and Industrial Specialties remain comparatively weak.
